Metabolic Syndrome and Prostate Cancer: A Review

Clinical Oncology

Volumn 21, Issue 3, 2009, Pages 183-191

  Nobes, J P ^a   Langley, S E M ^a   Laing, R W ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation therapy; insulin resistance; metabolic syndrome; prostate cancer

Indexed keywords

ANTILIPEMIC AGENT; BICALUTAMIDE; ESTROGEN; GONADORELIN AGONIST; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUPRORELIN; METFORMIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE; TOREMIFENE;

ADJUVANT THERAPY; ANTIGEN DETECTION; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HORMONE INHIBITION; HUMAN; LIFESTYLE MODIFICATION; MEDLINE; METABOLIC SYNDROME X; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK REDUCTION;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; METABOLIC SYNDROME X; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 61649116368     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.11.013     Document Type: Article

References (69)

1. Available from:. http://info.cancerresearchuk.org/cancerstats/types/prostate/?a=5441
2. Office for National Statistics. Mortality statistics: cause, 2006 (2008), Office for National Statistics, Newport
3. ISD Online. Cancer incidence and mortality in Scotland 2008. Available from: http://www.isdscotland.org/isd/183.html.
4. Northern Ireland Cancer Registry. Cancer incidence and mortality in Northern Ireland (2006), Northern Ireland Cancer Registry, Belfast
5. Brown B.W., Brauner C., and Minotte M.C. Non-cancer deaths in white adult cancer patients. J Natl Cancer Inst 85 (1993) 979-987
6. Walsh P.C., DeWeese T.L., and Eisenberger M.A. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 166 (2001) 508-515 [discussion 515-516]
7. Kawakami J., Cowan J.E., Elkin E.P., et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 106 (2006) 1708-1714
8. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
9. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
10. Bolla M., van Tienhoven G., de Reijke T.M., et al. (EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups). Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC phase III trial 22961. J Clin Oncol 25 18S (2007) 5014
11. D'Amico A.V., Denham J.W., Bolla M., et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109 (2007) 2004-2010
12. Henderson A., Langley S.E., and Laing R.W. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 15 (2003) 318-321
13. Khaksar S.J., Langley S.E., Lovell D., et al. Interstitial low dose rate brachytherapy for prostate cancer-a focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 18 (2006) 513-518
14. McLeod D.G., Iversen P., See W.A., et al. Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247-254
15. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
16. Barry M.J., Delorenzo M.A., Walker-Corkery E.S., et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 98 (2006) 973-978
17. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol 25 (2007) 5359-5365
18. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
19. Ockrim J., Lalani el N., and Abel P. Therapy insight: parenteral estrogen treatment for prostate cancer-a new dawn for an old therapy. Nat Clin Pract Oncol 3 (2006) 552-563
20. Satariano W.A., Ragland K.E., and Van Den Eeden S.K. Cause of death in men diagnosed with prostate carcinoma. Cancer 83 (1998) 1180-1188
21. Lu-Yao G., Stukel T.A., and Yao S.L. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 171 (2004) 2285-2290
22. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
23. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
24. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
25. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
26. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
27. Basaria S., Lieb II J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56 (2002) 779-786
28. Diamond T.H., Higano C.S., Smith M.R., et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
29. Smith M.R. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer 2 (2003) 18-21
30. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
31. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
32. Dockery F., Bulpitt C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104 (2003) 195-201
33. Garnick M.B., Pratt C.M., Campion M., et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 22 (2004) [abstract 4578]
34. Haffner S.M., Mykkanen L., Valdez R.A., et al. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 77 (1993) 1610-1615
35. Malkin C.J., Pugh P.J., Jones R.D., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 3313-3318
36. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
37. Nobes J., Laing R.W., and Langley S.E.M. Male health and the metabolic syndrome. Urology News 12 (2008) 6-10
38. Muller M., Grobee D.E., den Tonkelaar I., et al. Endogenous sex hormones and metabolic syndrome in ageing men. J Clin Endocrinol Metab 90 (2005) 2618-2623
39. Gale E.A. Is there really an epidemic of type 2 diabetes?. Lancet 362 (2003) 503-504
40. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
42. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
43. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
44. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
45. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabet Care 27 (2004) 1036-1041
46. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 (2006) 581-588
47. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
48. Lage M., Barber B.L., and Markus R.A. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70 (2007) 1104-1108
49. Derweesh I., Diblasio C.J., Kincade M.C., et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100 (2007) 1060-1065
50. Smith M.R., Lee H., McGovern F., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112 (2008) 2188-2194
51. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
52. Salpeter S., Greyber E., Pasternak G., and Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 25 (2007) CD002967
53. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26 (2008) 1824-1829
54. Kumar N.B., Cantor A., Allen K., et al. Android obesity at diagnosis and breast carcinoma survival: evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer 88 (2000) 2751-2757
55. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36 (2000) 1224-1228
56. Goodwin P.J., Ennis M., Pritchard K., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20 (2002) 42-51
57. Harvie N.M., Campbell I.T., Baildam A., et al. Energy balance in early breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 83 (2004) 201-210
58. Tande A.J., Platz E.A., and Folsom A.R. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164 (2006) 1094-1102
59. Cowey S., and Hardy R.W. The metabolic syndrome: a high-risk state for cancer?. Am J Pathol 169 (2006) 1505-1522
60. Chan J.M., Stampfer M.J., Giovannucci E., et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res Suppl A (2000) S32-S33
61. Laukkanen J.A., Laaksonen D.E., Niskanen L., et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13 (2004) 1646-1650
62. Venkateswaran V., Haddad A.Q., Fleshner N.E., et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99 (2007) 1793-1800
63. Mistry T., Digby J.E., Desai K.M., et al. Obesity and prostate cancer: a role for adipokines. Eur Urol 52 (2007) 46-53
64. Brown M.D., Hart C.A., Gazi E., et al. Promotion of prostatic metastatic migration towards human bone marrow stoma by omega 6 and its inhibition by omega 3 PUFAs. Br J Cancer 94 (2006) 842-853
65. Gazi E., Hart C., Clarke N.W., et al. Monitoring uptake and metabolism of an isotopically labelled fatty acid in prostate cancer cells using FTIT microspectroscopy. Eur Urol Suppl 6 (2007) 82
66. Tokuda Y., Satoh Y., Fujiyama C., et al. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 91 (2003) 716-720
67. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
68. Smith M.R., Bae K., Efstathiou J.A., et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol 26 (2008) 4333-4339
69. Freedland S.J., and Platz E.A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29 (2007) 88-97